Celltrion Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Celltrion hat ein Gesamteigenkapital von ₩16,993.9B und eine Gesamtverschuldung von ₩2,143.3B, wodurch sich der Verschuldungsgrad auf 12.6% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen ₩20,127.1B bzw. ₩3,133.2B. Celltrion Das EBIT des Unternehmens beträgt ₩373.9B, so dass der Zinsdeckungsgrad 22.3 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von ₩1,030.8B.

Wichtige Informationen

12.6%

Verhältnis von Schulden zu Eigenkapital

₩2.14t

Verschuldung

Zinsdeckungsgrad	22.3x
Bargeld	₩1.03t
Eigenkapital	₩16.99t
Gesamtverbindlichkeiten	₩3.13t
Gesamtvermögen	₩20.13t

Jüngste Berichte zur Finanzlage

Recent updates

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Jun 26

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

May 22

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Apr 30

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Mar 25

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Mar 19

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

May 05

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Mar 25

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Mar 15

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

Feb 24

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Feb 03

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Jan 13

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Dec 23

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Dec 02

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: A068270Die kurzfristigen Aktiva des Unternehmens (₩5,229.7B) übersteigen seine kurzfristigen Passiva (₩2,889.4B).

Langfristige Verbindlichkeiten: A068270Die kurzfristigen Vermögenswerte des Unternehmens (₩5,229.7B) übersteigen seine langfristigen Verbindlichkeiten (₩243.8B).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: A068270Die Nettoverschuldung im Verhältnis zum Eigenkapital (6.5%) wird als zufriedenstellend angesehen.

Schulden abbauen: A068270 Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 18.9% auf 12.6% zurückgegangen.

Schuldendeckung: A068270Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (20.2%).

Zinsdeckung: A068270Die Zinszahlungen für die Schulden des Unternehmens sind durch das EBIT (22.3x Coverage) gut gedeckt.

Celltrion Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 6/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Recent updates

Celltrion, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Celltrion Presents 2-Year Post-Hoc Analysis Findings for Subcutaneous Infliximab (CT-P13 SC), Highlighting Dose Escalation as an Option for Managing Loss of Response in Inflammatory Bowel Disease

Now 21% overvalued after recent price rise

Now 21% overvalued after recent price rise

European Commission Approves Celltrion's SteQeyma (CT-P43) A Biosimilar to Stelara (ustekinumab), for the Treatment of Multiple Chronic Inflammatory Diseases

Consensus EPS estimates fall by 21%

Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden

Celltrion Showcases Promising Results in Phase III study for CT-P47, A Biosimilar Candidate of Roactemra® (Tocilizumab) in Patients with Rheumatoid Arthritis (RA) at EULAR 2024

Celltrion Receives European Commission Approval of Omlyclo® (CT-P39), the First and Only Omalizumab Biosimilar Approved in Europe

Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)

First quarter 2024 earnings released: EPS: ₩108 (vs ₩1,156 in 1Q 2023)

Now 21% overvalued after recent price rise

Celltrion, Inc. (KRX:068270) Not Flying Under The Radar

Consensus EPS estimates fall by 14%

Celltrion's (KRX:068270) Profits May Not Reveal Underlying Issues

Full year 2023 earnings released: EPS: ₩3,759 (vs ₩3,664 in FY 2022)

We Think Celltrion (KRX:068270) Can Stay On Top Of Its Debt

Consensus EPS estimates fall by 16%

Celltrion, Inc., Annual General Meeting, Mar 26, 2024

Celltrion Presents New Two-Year Data for Subcutaneous Injectiximab (CT-P13 SC) in Inflammative Bowel Disease (IBD)

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 22%

Upcoming dividend of ₩500 per share at 0.3% yield

Consensus EPS estimates fall by 19%

Celltrion, Inc. to Report Nine Months, 2023 Results on Nov 07, 2023

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Celltrion, Inc. agreed to acquire a 64.46% stake in Celltrion Healthcare Co., Ltd. (KOSDAQ:A091990) for KRW 6.7 billion

First quarter 2023 earnings released: EPS: ₩1,156 (vs ₩756 in 1Q 2022)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Celltrion Healthcare Announces Canadian Approval of Vegzelma® (Bevacizumab for Injection) for the Treatment of Five Types of Cancer

Upcoming dividend of ₩375 per share

Now 20% undervalued after recent price drop

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: ₩1,328 (vs ₩907 in 2Q 2021)

Price target increased to ₩210,861

Consensus forecasts updated

Investor sentiment improved over the past week

Price target decreased to ₩194,520

Less than half of directors are independent

Now 20% undervalued after recent price drop

Price target decreased to ₩218,897

Full year 2021 earnings: EPS misses analyst expectations

Consensus revenue estimates increase by 10%

Celltrion, Inc Ordinary Shares to Be Deleted from Other OTC

Price target decreased to ₩277,071

Third quarter 2021 earnings released: EPS ₩992 (vs ₩1,251 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ₩919 (vs ₩1,013 in 2Q 2020)

Consensus EPS estimates fall to ₩4,214

Here's Why I Think Celltrion (KRX:068270) Is An Interesting Stock

Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapid Test Kit – DiaTrust COVID-19 Ag Rapid Test

Robust Earnings May Not Tell The Whole Story For Celltrion (KRX:068270)

Here's What Celltrion, Inc.'s (KRX:068270) Shareholder Ownership Structure Looks Like

Is Celltrion's (KRX:068270) Share Price Gain Of 208% Well Earned?

New 90-day low: ₩300,500

Celltrion, Inc., Annual General Meeting, Mar 26, 2021

Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tackle COVID-19 Variant Spread Using Its Antibody Development Platform

Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Authorisation

Celltrion (KRX:068270) Has A Rock Solid Balance Sheet

Celltrion Group Announces Positive Top-Line Efficacy and Safety Data from Global Phase II/III Clinical Trial of COVID-19 Treatment Candidate CT-P59

Is Celltrion, Inc.'s (KRX:068270) Latest Stock Performance A Reflection Of Its Financial Health?

Does Celltrion (KRX:068270) Deserve A Spot On Your Watchlist?

Are Institutions Heavily Invested In Celltrion, Inc.'s (KRX:068270) Shares?

Celltrion, Inc. (KOSE:A068270) completed the acquisition of portfolio of select non-core otc and prescription pharmaceutical products exclusively in Asia Pacific from Takeda Pharmaceutical Company Limited (TSE:4502).

Celltrion Completes Enrolment for Global Phase II Clinical Trial with COVID-19 Treatment Candidate CT-P59

New 90-day high: ₩330,000

Celltrion Presents Efficacy and Safety Data for Potential Covid-19 Treatment Candidate Ct-P59 in Patients with Mild Symptoms

New 90-day low: ₩245,500

New 90-day low: ₩278,500